Kai-Chun Cheng1,2,3, Yu-Jen Wu4, Kai-Hung Cheng5,6, Kai-Yuan Cheng7, Kuo-Jen Chen1, Wen-Chuan Wu2,8, Po-Yen Lee2, Cheng-Hsien Chang9,10. 1. Department of Ophthalmology, Kaohsiung Municipal Hsiao-kang Hospital, Kaohsiung, Taiwan. 2. Department of Ophthalmology, Kaohsiung Medical University Hospital, No.100, Zihyou 1st Road, Sanmin District, Kaohsiung, 807, Taiwan. 3. Department of Optometry, Shu-Zen junior College of Medicine and Management, Kaohsiung, Taiwan. 4. Department of Biological Science and Technology, Meiho University, Pingtung, Taiwan. 5. Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. 6. Department of Internal Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 7. Department of Otolaryngology, Head and Neck Surgery, Ministry of Health and Welfare Pingtung Hospital, Pingtung, Taiwan. 8. Department of Ophthalmology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 9. Department of Ophthalmology, Kaohsiung Medical University Hospital, No.100, Zihyou 1st Road, Sanmin District, Kaohsiung, 807, Taiwan. ophchang@cc.kmu.edu.tw. 10. Department of Ophthalmology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. ophchang@cc.kmu.edu.tw.
Abstract
PURPOSE: This study surveyed the novel autoantigens expressed in the orbital fat tissue of patients with Graves' orbitopathy (GO) and explored the possibility of the autoantibodies against novel autoantigens as biomarkers for GO. METHODS: We used immuno-proteomic methods to survey novel autoantigens expressed in the orbit fat tissue of GO patients and confirmed by enzyme-linked immunosorbent assay (ELISA). RESULTS: One protein spot (aldehyde dehydrogenase 2 (ALDH2)) revealed high reactivity with the GO serum than did the healthy control serum and was further verified by ELISA. We found that the plasma anti-ALDH2 antibody level was increased in GO patients compared to healthy control donors. In addition, anti-ALDH2 antibody level was correlated with GO activity classified by clinical activity score(r = 0.588, p < 0.001, using Pearson's correlation). CONCLUSIONS: These increased levels of anti-ALDH2 antibody in GO serum suggested that ALDH2 could attribute target autoantigen in GO, and anti-ALDH2 autoantibody might serve as a biomarker for GO and help to predict disease activity.
PURPOSE: This study surveyed the novel autoantigens expressed in the orbital fat tissue of patients with Graves' orbitopathy (GO) and explored the possibility of the autoantibodies against novel autoantigens as biomarkers for GO. METHODS: We used immuno-proteomic methods to survey novel autoantigens expressed in the orbit fat tissue of GO patients and confirmed by enzyme-linked immunosorbent assay (ELISA). RESULTS: One protein spot (aldehyde dehydrogenase 2 (ALDH2)) revealed high reactivity with the GO serum than did the healthy control serum and was further verified by ELISA. We found that the plasma anti-ALDH2 antibody level was increased in GO patients compared to healthy control donors. In addition, anti-ALDH2 antibody level was correlated with GO activity classified by clinical activity score(r = 0.588, p < 0.001, using Pearson's correlation). CONCLUSIONS: These increased levels of anti-ALDH2 antibody in GO serum suggested that ALDH2 could attribute target autoantigen in GO, and anti-ALDH2 autoantibody might serve as a biomarker for GO and help to predict disease activity.
Authors: M N Gerding; J W van der Meer; M Broenink; O Bakker; W M Wiersinga; M F Prummel Journal: Clin Endocrinol (Oxf) Date: 2000-03 Impact factor: 3.478